clinical trial · NCT07796100
A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer
Zai Lab (Shanghai) Co., Ltd.·phase3·not yet recruiting·n = 530
Extensive-Stage Small Cell Lung CancerZL-1310 in combination with Atezolizumab or DurvalumabCarboplatin/Etoposide in Combination with Atezolizumab followed by maintenance Atezolizumab with LurbinectedinCarboplatin/Etoposide or Cistplatin/Etoposide in Combination with Durvalumab induction followed by Durvalumab maintenance
brief summary
The purpose of this study is to evaluate the efficacy and safety of ZL-1310 in combination with a checkpoint inhibitor compared to standard first-line therapy in participants with Extensive-Stage Small Cell Lung Cancer.
started
Dec 31, 2026
primary completion
Jun 30, 2030
completion
Jun 30, 2031
last updated
Aug 31, 2026
official title
A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody-drug Conjugate (ADC) in Combination With a Checkpoint Inhibitor Compared to Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol